Tolvaptan inhibits ERK-dependent cell proliferation, Cl- secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin

American Journal of Physiology - Renal Physiology

Volumn 301, Issue 5, 2011, Pages

  Reif, Gail A ^a   Yamaguchi, Tamio ^a,b   Nivens, Emily ^a   Fujiki, Hiroyuki ^c   Pinto, Cibele S ^a   Wallace, Darren P ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Cyclic AMP; MAP kinase; Polycystic kidney disease; V2 receptor

Indexed keywords

ARGIPRESSIN; CHLORIDE; CYCLIC AMP; MITOGEN ACTIVATED PROTEIN KINASE; TOLVAPTAN;

ARTICLE; AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE; CELL PROLIFERATION; CONTROLLED STUDY; CYCLIC AMP BLOOD LEVEL; CYST; ENZYME ACTIVITY; EPITHELIUM CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INCUBATION TIME; KIDNEY POLYCYSTIC DISEASE; MONOLAYER CULTURE; PRIORITY JOURNAL; SECRETION; SHORT CIRCUIT CURRENT; SIGNAL TRANSDUCTION;

EID: 80055089806     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00243.2011     Document Type: Article

References (52)

1. Banales JM, Masyuk TV, Gradilone SA, Masyuk AI, Medina JF, LaRusso NF. The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). Hepatology 49: 160-174, 2009.
2. Belibi FA, Reif G, Wallace DP, Yamaguchi T, Olsen L, Li H, Helmkamp GM Jr, Grantham JJ. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 66: 964-973, 2004.
3. Boucher CA, Ward HH, Case RL, Thurston KS, Li X, Needham A, Romero E, Hyink D, Qamar S, Roitbak T, Powell S, Ward C, Wilson PD, Wandinger-Ness A, Sandford RN. Receptor protein tyrosine phosphatases are novel components of a polycystin complex. Biochim Biophys Acta 1812: 1225-1238, 2011.
4. Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr. Pharmacology of vasopressin antagonists. Heart Fail Rev 14: 75-82, 2009.
5. Danielsen H, Pedersen EB, Nielsen AH, Herlevsen P, Kornerup HJ, Posborg V. Expansion of extracellular volume in early polycystic kidney disease. Acta Med Scand 219: 399-405, 1986.
6. Decaux G, Soupart A, Vassart G. Nonpeptide arginine-vasopressin antagonists: the vaptans. Lancet 371: 1624-1632, 2008.
7. Delmas P. Polycystins: from mechanosensation to gene regulation. Cell 118: 145-148, 2004.
8. Devuyst O, Burrow CR, Smith BL, Agre P, Knepper MA, Wilson PD. Expression of aquaporins-1 and -2 during nephrogenesis and in autosomal dominant polycystic kidney disease. Am J Physiol Renal Fluid Electrolyte Physiol 271: F169-F183, 1996.
9. Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med 329: 332-342, 1993.
10. Gabow PA, Kaehny WD, Johnson AM, Duley IT, Manco-Johnson M, Lezotte DC, Schrier RW. The clinical utility of renal concentrating capacity in polycystic kidney disease. Kidney Int 35: 675-680, 1989.
11. Gattone VH 2nd, Maser RL, Tian C, Rosenberg JM, Branden MG. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev Genet 24: 309-318, 1999.
12. Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9: 1323-1326, 2003.
13. Gresh L, Fischer E, Reimann A, Tanguy M, Garbay S, Shao X, Hiesberger T, Fiette L, Igarashi P, Yaniv M, Pontoglio M. A transcriptional network in polycystic kidney disease. EMBO J 23: 1657-1668, 2004.
14. Hanaoka K, Qian F, Boletta A, Bhunia AK, Piontek K, Tsiokas L, Sukhatme VP, Guggino WB, Germino GG. Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents. Nature 408: 990-994, 2000.
15. Hauptman PJ, Zimmer C, Udelson J, Shoaf SE, Mallikaarjun S, Bramer SL, Orlandi C. Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure. J Cardiovasc Pharmacol 46: 609-614, 2005.
16. Houslay MD, Milligan G. Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem Sci 22: 217-224, 1997.
17. Lantinga-van Leeuwen IS, Dauwerse JG, Baelde HJ, Leonhard WN, van de Wal A, Ward CJ, Verbeek S, Deruiter MC, Breuning MH, de Heer E, Peters DJ. Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease. Hum Mol Genet 13: 3069-3077, 2004.
18. - cotransporter-dependent cystic dilation. J Am Soc Nephrol 17: 3424-3437, 2006.
19. Mangoo-Karim R, Ye M, Wallace DP, Grantham JJ, Sullivan LP. Anion secretion drives fluid secretion by monolayers of cultured human polycystic cells. Am J Physiol Renal Fluid Electrolyte Physiol 269: F381-F388, 1995.
20. Marion V, Schlicht D, Mockel A, Caillard S, Imhoff O, Stoetzel C, van Dijk P, Brandt C, Moulin B, Dollfus H. Bardet-Biedl syndrome highlights the major role of the primary cilium in efficient water reabsorption. Kidney Int 79: 1013-1025, 2011.
21. Martinez-Maldonado M, Yium JJ, Eknoyan G, Suki WN. Adult polycystic kidney disease: studies of the defect in urine concentration. Kidney Int 2: 107-113, 1972.
22. Michalski A, Grzeszczak W. The effect of hypervolemia on electrolyte level and and level of volume regulating hormones in patients with autosomal dominant polycystic kidney disease. Pol Arch Med Wewn 96: 329-343, 1996.
23. Nagao S, Nishii K, Katsuyama M, Kurahashi H, Marunouchi T, Takahashi H, Wallace DP. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 17: 2220-2227, 2006.
24. Nauli SM, Rossetti S, Kolb RJ, Alenghat FJ, Consugar MB, Harris PC, Ingber DE, Loghman-Adham M, Zhou J. Loss of polycystin-1 in human cyst-lining epithelia leads to ciliary dysfunction. J Am Soc Nephrol 17: 1015-1025, 2006.
25. Nguyen AN, Wallace DP, Blanco G. Ouabain binds with high affinity to the Na,K-ATPase in human polycystic kidney cells and induces extracellular signal-regulated kinase activation and cell proliferation. J Am Soc Nephrol 18: 46-57, 2007.
26. Parnell SC, Magenheimer BS, Maser RL, Rankin CA, Smine A, Okamoto T, Calvet JP. The polycystic kidney disease-1 protein, polycystin-1, binds and activates heterotrimeric G-proteins in vitro. Biochem Biophys Res Commun 251: 625-631, 1998.
27. Pei Y. Practical genetics for autosomal dominant polycystic kidney disease. Nephron Clin Pract 118: c19-c30, 2011.
28. Plosker GL. Tolvaptan. Drugs 70: 443-454, 2010.
29. Serradeil-Le Gal C, Lacour C, Valette G, Garcia G, Foulon L, Galindo G, Bankir L, Pouzet B, Guillon G, Barberis C, Chicot D, Jard S, Vilain P, Garcia C, Marty E, Raufaste D, Brossard G, Nisato D, Maffrand JP, Le Fur G. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest 98: 2729-2738, 1996.
30. Smith LA, Bukanov NO, Husson H, Russo RJ, Barry TC, Taylor AL, Beier DR, Ibraghimov-Beskrovnaya O. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol 17: 2821-2831, 2006.
31. Sullivan LP, Wallace DP, Grantham JJ. Chloride and fluid secretion in polycystic kidney disease. J Am Soc Nephrol 9: 903-916, 1998.
32. Thomson RB, Mentone S, Kim R, Earle K, Delpire E, Somlo S, Aronson PS. Histopathological analysis of renal cystic epithelia in the Pkd2WS25/_ mouse model of ADPKD. Am J Physiol Renal Physiol 285: F870-F880, 2003.
33. Torres VE, Chapman AB, Grantham JJ, Watnick TJ, Ouyang J, Krasa HB, Czerwiec FS. TEMPO 2/4 update: changes in ADPKD total kidney volume and eGFR with 3 years of tolvaptan and after withdrawal. J Am Soc Nephrol 21: 528A, 2010.
34. Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS. Rationale and design of the TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3-4 study. Am J Kidney Dis 57: 692-699, 2011.
35. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10: 363-364, 2004.
36. Vandorpe DH, Chernova MN, Jiang L, Sellin LK, Wilhelm S, Stuart-Tilley AK, Walz G, Alper SL. The cytoplasmic C-terminal fragment of polycystin-1 regulates a Ca2&-permeable cation channel. J Biol Chem 276: 4093-4101, 2001.
37. Verani RR, Silva FG. Histogenesis of the renal cysts in adult (autosomal dominant) polycystic kidney disease: a histochemical study. Mod Pathol 1: 457-463, 1988.
38. Wallace DP. Cyclic AMP-mediated cyst expansion. Biochim Biophys Acta 1812: 1291-1300, 2011.
39. Wallace DP, Christensen M, Reif G, Belibi F, Thrasher B, Herrell D, Grantham JJ. Electrolyte and fluid secretion by cultured human inner medullary collecting duct cells. Am J Physiol Renal Physiol 283: F1337-F1350, 2002.
40. Wallace DP, Grantham JJ, Sullivan LP. Chloride and fluid secretion by cultured human polycystic kidney cells. Kidney Int 50: 1327-1336, 1996.
41. Wallace DP, Quante MA, Reif GA, Nivens E, Ahmed F, Hempson SJ, Blanco G, Yamaguchi T. Periostin induces proliferation of human autosomal dominant polycystic kidney cells through alphaV-integrin receptor. Am J Physiol Renal Physiol 295: F1463-F1471, 2008.
42. Wang X, Gattone V 2nd, Harris PC, Torres VE. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 16: 846-851, 2005.
43. Wang X, Wu Y, Ward CJ, Harris PC, Torres VE. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 19: 102-108, 2008.
44. Wu G, D'Agati V, Cai Y, Markowitz G, Park JH, Reynolds DM, Maeda Y, Le TC, Hou H Jr, Kucherlapati R, Edelmann W, Somlo S. Somatic inactivation of Pkd2 results in polycystic kidney disease. Cell 93: 177-188, 1998.
45. Xia S, Li X, Johnson T, Seidel C, Wallace DP, Li R. Polycystindependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts. Development 137: 1075-1084, 2010.
46. Yamaguchi T, Hempson SJ, Reif GA, Hedge AM, Wallace DP. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol 17: 178-187, 2006.
47. Yamaguchi T, Nagao S, Kasahara M, Takahashi H, Grantham JJ. Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 30: 703-709, 1997.
48. Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, Grantham JJ. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 63: 1983-1994, 2003.
49. Yamaguchi T, Pelling JC, Ramaswamy NT, Eppler JW, Wallace DP, Nagao S, Rome LA, Sullivan LP, Grantham JJ. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 57: 1460-1471, 2000.
50. Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP. Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growthstimulated phenotype. J Biol Chem 279: 40419-40430, 2004.
51. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, Yamada Y, Tsujimae K, Aoyama M, Kotosai K, Ogawa H, Yamashita H, Kondo K, Tominaga M, Tsujimoto G, Mori T. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287: 860-867, 1998.
52. Yang J, Zhang S, Zhou Q, Guo H, Zhang K, Zheng R, Xiao C. PKHD1 gene silencing may cause cell abnormal proliferation through modulation of intracellular calcium in autosomal recessive polycystic kidney disease. J Biochem Mol Biol 40: 467-474, 2007.